Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$19.7M in Q4 2024 → $14.2M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Kaltura Inc | 90.8% | Unchanged | 8,962,707 | $12.9M |
| Janux Therapeutics Inc | 9.2% | Added 23% | 53,300 | $1.3M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Janux Therapeutics Inc | Added | +10,000 | +$244K | 9.2% |
quarter ended June 30, 2025 · filed July 25, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Janux Therapeutics Inc | New | +43,300 | +$1M | 5.3% |
quarter ended March 31, 2025 · filed May 15, 2025
No position changes this quarter.
Loading...
